3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.
Madrigal Pharmaceuticals, Inc.
MDGL
MDGL
$89.23
$0.96
1.1%
BATS BZX Real Time Price as of October 23, 2019, 11:26 a.m. EDT
View Interactive MDGL Charts
Madrigal Pharmaceuticals, Inc.
News & Analysis: Madrigal Pharmaceuticals, Inc.
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
Which of these NASH-oriented biotechs is the better buy?
3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
A new year and reasons to remain hopeful for these three biotechs are around the corner.
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Impressive results from a potential competitor took the shine off this biotech's experimental NASH treatment.
Why Madrigal Pharmaceuticals Stock Slumped in October
Madrigal's stock continued to cool off last month, but another rally could be close at hand.
Better Buy: Intercept Pharmaceuticals Inc. vs. Madrigal Pharmaceuticals
Which stock wins in a matchup between these biotechs hoping for success with promising NASH drugs?
Here's Why Viking Therapeutics Skyrocketed 33% in September
Solid phase 2 data has investors excited about the biotech's future.
3 Top Stocks for Investing in Pharma's Next $35 Billion Market
Here's why these three biotechs could come out ahead in the race to tackle a leading cause of liver failure.
Why Madrigal Pharmaceuticals Stock Is Getting Hammered Today
The company is apparently demanding top dollar in a buyout scenario.
The 4 Best Biotech Stocks of 2018 (So Far)
Find out what's pushing shares of these biotechs through the roof.
